Pfizer and Biohaven Pharmaceuticals have entered into an agreement under which Pfizer will acquire Biohaven, the maker of NURTEC ODT, a dual-acting migraine therapy approved for both acute treatment and episodic prevention of migraine in adults. Pfizer will pay approximately $11.6 billion to make the acquisition, which includes Biohaven’s calcitonin gene-related peptide (CGRP) programs including: • Rimegepant—approved in the U.S. under the trade name, NURTEC ODT, for both the acute treatme...